Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Ca2+ signalling in cardiac muscle: the importance of balances.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
   Review
2. Flecainide Specifically Targets the Monovalent Countercurrent Through the Cardiac Ryanodine Receptor, While a Dominant Opposing CaInternational journal of molecular sciences · 2024
   Article
3. Store-Operated CaJournal of clinical medicine · 2023
   Review
4. Molecular, Subcellular, and Arrhythmogenic Mechanisms in Genetic RyR2 Disease.Biomolecules · 2022
   Review

Corrections and comments

• Comment on
  RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.2021

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as